TI
TCRR

Trexquant Investment’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Trexquant Investment’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-171,306
Closed -$798K – 1842
2021
Q4 		$798K Buy
171,306
+82,396
+93% +$515K 0.05% 464
2021
Q3 		$757K Buy
88,910
+74,258
+507% +$1.05M 0.06% 392
2021
Q2 		$240K Buy
+14,652
New +$296K 0.02% 821

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Trexquant Investment's TCRR Position: Q1 2022 in Review

Trexquant Investment sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2022, closing a stake of 171,306 shares — an estimated $798K sold.

Trexquant Investment first reported a position in TCRR in Q2 2021 and held it in 3 quarters. The position peaked at $798K in Q4 2021. 94 funds tracked by Wall St. Rank hold TCRR as of Q1 2022.

  • Trexquant Investment reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Trexquant Investment sold 171,306 TCR2 Therapeutics Inc. Common Stock shares in Q1 2022, an estimated $798K.
  • Trexquant Investment first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Trexquant Investment's TCR2 Therapeutics Inc. Common Stock position peaked at $798K in Q4 2021.
  • 94 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2022.

Based on Trexquant Investment's 13F filing for Q1 2022, filed 13 May 2022.